financetom
Business
financetom
/
Business
/
High Tide Closed $15 Million in Subordinated Debt Facility
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
High Tide Closed $15 Million in Subordinated Debt Facility
Aug 2, 2024 12:05 PM

02:31 PM EDT, 08/02/2024 (MT Newswires) -- High Tide Inc. ( HITI ) on Friday announced the initial closing of its previously disclosed subordinated debt facility of $1,000 principal subordinate secured debentures of the company for aggregate gross proceeds of $15 million at a price of $900 per debenture.

A statement noted the debentures will mature on July 31, 2029, and bear interest at a fixed rate of 12% per annum on drawn amounts, payable quarterly.

Friday's statement said the debentures will be drawn in two tranches: $10 million principal amount which has been drawn on the initial closing; and $5 million in November 2024.

The company issued an aggregate of 230,760 common shares at a price of $3.47 per common shares to the lenders.

Net proceeds of the Facility will be used for debt repayment, ongoing development of the company's business model and general working capital purposes.

HITI was down $0.13 or 5.1% at $2.40.

Price: 2.39, Change: -0.14, Percent Change: -5.53

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BCB Bancorp Q3 net income falls 36%, but interest margins rise
BCB Bancorp Q3 net income falls 36%, but interest margins rise
Oct 27, 2025
Overview * BCB Bancorp ( BCBP ) Q3 net income falls to $4.3 mln from $6.7 mln a year ago * EPS for Q3 2025 was $0.22, down from $0.36 in Q3 2024 * Net interest margin increased to 2.88% in Q3 2025 from 2.58% a year earlier Outlook * Company did not provide specific guidance for future quarters or...
Elicio Therapeutics' ELI-002 7P Candidate Shows Positive T cell Responses in Ongoing Phase 2 Trial
Elicio Therapeutics' ELI-002 7P Candidate Shows Positive T cell Responses in Ongoing Phase 2 Trial
Oct 27, 2025
08:37 AM EDT, 10/27/2025 (MT Newswires) -- Elicio Therapeutics ( ELTX ) said Monday that preliminary analysis from its phase 2 trial indicated that 99% of patients assessed for Human Leukocyte Antigen background induced mKRAS-specific T cell responses after treatment with ELI-002 7P. The induction of mKRAS-specific T cell responses suggest that ELI-002 7P may address a broad patient population...
Parkland Q3 Adjusted Earnings Rise 70% Ahead of its US$9.1-Billion Sale to Sunoco
Parkland Q3 Adjusted Earnings Rise 70% Ahead of its US$9.1-Billion Sale to Sunoco
Oct 27, 2025
08:33 AM EDT, 10/27/2025 (MT Newswires) -- Parkland (PKI.TO) Monday said its third-quarter adjusted profit rose 70% in its final report ahead of the company's sale to Sunoco ( SUN ) . The refiner and gas-stop operator's adjusted profit, excluding most one-time items, rose to $180 million, or $1.03 per share, from $106 million, or $0.61, in the year-prior quarter....
Organon Appoints Joseph Morrissey as Interim CEO After Investigation Finds Possible Sales Practice Irregularities
Organon Appoints Joseph Morrissey as Interim CEO After Investigation Finds Possible Sales Practice Irregularities
Oct 27, 2025
08:33 AM EDT, 10/27/2025 (MT Newswires) -- Organon (OGN) said Monday its board has appointed the company's head of manufacturing and supply Joseph Morrissey as interim CEO. Morrissey was most recently the head of Merck's ( MRK ) animal health global manufacturing and supply division, Organon said. Kevin Ali, previously CEO, resigned after an audit discovered possible sales practice irregularities...
Copyright 2023-2026 - www.financetom.com All Rights Reserved